• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab in patients with advanced melanoma: analysis from KEYNOTE-006

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Long, G. V.
    Arance, A.
    Mortier, L.
    Lorigan, Paul C
    Blank, C.
    Mohr, P.
    Schachter, J.
    Grob, J. J.
    Lotem, M.
    Middleton, M. R.
    Neyns, B.
    Steven, N.
    Ribas, A.
    Walpole, E.
    Carlino, M. S.
    Lebbe, C.
    Sznol, M.
    Jensen, E.
    Leiby, M. A.
    Ibrahim, N.
    Robert, C.
    Show allShow less
    Affiliation
    Melanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, NSW, Australia
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background: Antitumor activity of ipilimumab or BRAF ± MEK inhibition (BRAFi ± MEKi) following pembrolizumab in melanoma is poorly characterized. Patients and methods: In the phase 3 KEYNOTE-006 study, patients with unresectable stage III/IV melanoma received pembrolizumab 10 mg/kg once every 2 or 3 weeks (Q3W) or ipilimumab 3 mg/kg Q3W. The current post hoc analysis evaluates outcomes with ipilimumab or BRAFi ± MEKi as first subsequent systemic therapy after pembrolizumab and includes patients who completed or discontinued pembrolizumab after ≥1 dose. Pembrolizumab arms were pooled. Results: At data cutoff (December 4, 2017), median follow-up was 46.9 months. Of 555 pembrolizumab-treated patients, first subsequent therapy was ipilimumab for 103 (18.6%) and BRAFi ± MEKi for 59 (10.6%) (33 received BRAFi + MEKi, 26 BRAFi alone; 37 [62.7%] were BRAFi ± MEKi-naïve). In the subsequent ipilimumab group, ORR with previous pembrolizumab was 17.5% (1 complete response [CR]; 17 partial response [PR]); 79.6% had discontinued pembrolizumab due to progressive disease (PD); median OS was 21.5 months. ORR with subsequent ipilimumab was 15.5%; 11/16 responses (8 CRs; 3 PRs) were ongoing. ORR with subsequent ipilimumab was 9.7% for patients with PD as best response to pembrolizumab. Median OS from ipilimumab initiation was 9.8 months. In the subsequent BRAFi ± MEKi group, ORR with previous pembrolizumab was 13.5% (8 PR); 76.3% had discontinued pembrolizumab due to PD; median OS was 17.9 months. ORR with subsequent BRAFi ± MEKi was 30.5%, 7/18 responses (4 CR, 3 PR) were ongoing. Median OS from BRAFi ± MEKi initiation was 12.9 months. ORR for BRAFi ± MEKi-naïve patients who received subsequent BRAFi ± MEKi was 43.2%; 6/16 were ongoing (3 CR, 3 PR). Conclusions: Ipilimumab and BRAFi ± MEKi have antitumor activity as first subsequent therapy after pembrolizumab in patients with advanced melanoma.
    Citation
    Long GV, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, et al. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006 [Internet]. Annals of Oncology. Elsevier BV; 2021.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624765
    DOI
    10.1016/j.annonc.2021.10.010
    PubMed ID
    34710571
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.10.010
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.10.010
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
    • Authors: Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O
    • Issue date: 2020 Aug 1
    • Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
    • Authors: Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P
    • Issue date: 2018 Mar
    • Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    • Authors: Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR
    • Issue date: 2019 Dec
    • Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
    • Authors: Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino M, Menzies A, Long G
    • Issue date: 2022 Jul
    • Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
    • Authors: Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ
    • Issue date: 2017 Jan
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.